Congresswoman Pressley says Celgene put profit over people at House hearing

Massachusetts Representative Ayanna Pressley says at a House Oversight and Reform Committee hearing with pharmaceutical executives about drug pricing that multiple myeloma was a cancer compromised the immune system in place them at increased risk especially during the ongoing coronavirus pandemic, Revlimid could treat multiple myeloma but for no other reason than greed Celgene raised its price from $215 to $719, asking former Celgene CEO Mark Alles if he believed pharmaceutical companies should prioritize people over profit, Alles answering could only do well by doing good, had to take care of people to be successful the prioritize people medicines, Pressley interrupting to ask if people were put over profit, calling his answer in either yes or no so would take as a yes.